931 followers
Quick editorial. Anticiapte Lorlatinib will have a long median PFS among Asians than alectinib despite the excellent PFS achieved by ALESIA. https://t.co/KlrjHPi4R7 @ALKPositiveinc @ALKpositiveINT
Quick editorial. Anticiapte Lorlatinib will have a long median PFS among Asians than alectinib despite the excellent PFS achieved by ALESIA. https://t.co/KlrjHPi4R7 @ALKPositiveinc @ALKpositiveINT